Duncan NRI Faculty and Staff Publications

Language

English

Publication Date

3-3-2026

Journal

JNCI Cancer Spectrum

DOI

10.1093/jncics/pkag023

PMID

41795833

PMCID

PMC13032903

PubMedCentral® Posted Date

3-7-2026

PubMedCentral® Full Text Version

Post-print

Abstract

Molecular profiling has identified 3 groups of meningiomas, with MenG C tumors exhibiting the vast majority of recurrences. Efforts to find effective treatments for recurrent meningiomas have remained elusive. Higher WHO-grade meningiomas have exhibited greater Programmed Death Ligand 1 (PD-L1) expression through various methods, but the prognostic value of PD-L1 expression has not been described in the context of molecular profiling. Additionally, trials investigating PD-1/PD-L1-targeted immunotherapies have produced disappointing results. Here, we find that PD-L1 positivity, while prevalent in MenG C tumors, does not predict recurrence in the benign MenG A and B tumors. PD-L1 positivity also occurs independently of CDKN2A/B loss, a core component of the WHO grade that is regularly used in clinical trial selection criteria. Our results indicate that future clinical trials for PD-1/PD-L1 centric immunotherapies should select patients after molecularly profiling tumors to confirm aggressive MenG C status.

Keywords

Humans, B7-H1 Antigen, Meningioma, Meningeal Neoplasms, Female, Middle Aged, Male, Neoplasm Recurrence, Local, Aged, Prognosis, Adult, Cyclin-Dependent Kinase Inhibitor p16, Biomarkers, Tumor, Neoplasm Grading

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.